entertainment -WSS

entertainment

author：focus 2025-10-02 12:31:50 - browse：55

Adam's take main illustration — Molly Ferguson/STAT

Annovis Bio had my biotech bull%^&! meter running red after it made a late change to the design of a Phase 3 study in Parkinson’s disease. But then I got an extraordinary explanation from CEO Maria Maccecchini. Now, I’m less worried about data spin because, by her own admission, the odds that the study succeeds, post endpoint change, are a lot lower.

Results from the completed Parkinson’s study, which is investigating Annovis’ drug called buntanetap, are well past due because of what the company has described as ongoing “data cleaning efforts.” The delay was announced on Jan. 24. Two weeks later, on Feb. 6, the primary efficacy endpoint of the study was changed, according to an update posted to the U.S. government’s clinical trials database.

Red flag, I thought, until I emailed Maccecchini, asking for an explanation. In response, she told me Annovis made the key endpoint change in August, based on a recommendation from officials at the Food and Drug Administration after the agency had reviewed data from an interim analysis of the study. It took the company another six months to update the study design in the ClinicalTrials.gov database, for reasons she did not explain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Nobel honors Karikó and Weissman's enduring partnership

entertainment

WSS

Weight loss drug costs may need more research, senator suggests

Congress must reauthorize a committee to support older Americans

Lawsuit highlights wrinkle for disputes over surprise medical bills

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

CDC picks Alphabet's Verily for wasterwater surveillance contract

entertainment

entertainment

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

With Roe v Wade overturned, abortion providers work to adapt

Medicare details structure of new drug price negotiation program

Poor hospice wound care hurts patients and families

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

The United States is paying nearly triple for new Covid vaccines

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Study points to new risk in gene therapy death of Terry Horgan

hotspot

Weight loss drug costs may need more research, senator suggests

CDC picks Alphabet's Verily for wasterwater surveillance contract

Some top drug companies are starting to take action on climate

IVG is promising — but it won’t replace IVF quite yet

In key trial, Verve's treatment lowers cholesterol levels in patients

6 solutions to address cancer drug shortages and others

Wikipedia

entertainment

focus

explore